View Older Stories View More Recent Stories

Jan 4, 2019 07:30AM Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions
Jan 4, 2019 07:30AM Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions
Jan 4, 2019 07:30AM Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Jan 3, 2019 07:31AM Biogen (BIIB) Reports First Patient Enrollment in Phase 3b Study to Evaluate Extended Interval Dosing with Natalizumab in Multiple Sclerosis
Jan 3, 2019 07:30AM First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
Jan 3, 2019 07:30AM First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
Dec 20, 2018 12:20PM Biogen (BIIB) Applauds Quebec Decision to Cover SPINRAZA for broad population of SMA Patients
Dec 20, 2018 12:19PM Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
Dec 17, 2018 07:32AM Alkermes (ALKS) and Biogen (BIIB) Announce Submission of NDA to FDA for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Dec 6, 2018 07:33AM Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop, Commercialize Investigational Treatment BIIB067 for Subtype of Familial ALS Based on Positive Phase 1 Data
Dec 6, 2018 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Dec 6, 2018 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Nov 29, 2018 07:30AM International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Nov 29, 2018 07:30AM International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Oct 26, 2018 09:16AM Biogen (BIIB), Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 26, 2018 09:15AM Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Oct 26, 2018 09:15AM Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Oct 25, 2018 08:38AM Eisai, Biogen (BIIB) Announce Presentation of Additional Data From Phase II Trial of BAN2401 in Early AD at CTAD Conference
Oct 25, 2018 08:31AM Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Confere
Oct 25, 2018 08:31AM Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Confere
Oct 23, 2018 05:42AM Biogen (BIIB), UCB Report Topline Results from Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 23, 2018 01:00AM UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 23, 2018 01:00AM UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 18, 2018 07:30AM Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Oct 18, 2018 07:30AM Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Oct 17, 2018 05:49AM Biogen (BIIB) & Samsung Bioepis JV Announce European Union Launch of IMRALDI, an Adalimumab Biosimilar Referencing Humira
Oct 17, 2018 02:18AM Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market
Oct 17, 2018 02:00AM IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
Oct 17, 2018 02:00AM IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
Oct 11, 2018 07:30AM Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Oct 11, 2018 07:30AM Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Oct 8, 2018 05:58AM Biogen (BIIB) Reports New Interim Study Results from NURTURE
Oct 6, 2018 07:30AM New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
Oct 6, 2018 07:30AM New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
Oct 3, 2018 07:33AM Biogen (BIIB) to Present Data from its Neurology Pipeline at MDS
Oct 3, 2018 07:30AM Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
Oct 3, 2018 07:30AM Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
Oct 2, 2018 07:30AM Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
Oct 2, 2018 07:30AM Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
Oct 1, 2018 05:05AM Helsinn Group strengthens the Board with the appointment of Francesco Granata
Sep 4, 2018 07:30AM Biogen (BIIB) Reports Enrollment of First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
Sep 4, 2018 07:30AM Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
Sep 4, 2018 07:30AM Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
Aug 28, 2018 07:34AM Biogen (BIIB), Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational AD Treatment Aducanumab
Aug 28, 2018 07:30AM Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Aug 28, 2018 07:30AM Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Jul 26, 2018 08:01AM Facebook sends Nasdaq tumbling, but trade optimism boosts Dow
View More Recent Stories View Older Stories